---
title: "Camupepimut KRAS Vaccine Induces Strong Immune Responses in Phase 2 Pancreatic Cancer Trial"
id: "medical-news-today-0-experimental-pancreatic-cancer-vaccine-shows-promise-in-clinical-trial"
canonical_url: "https://medichelpline.com/clinical-feed/medical-news-today-0-experimental-pancreatic-cancer-vaccine-shows-promise-in-clinical-trial"
content_type: "clinical_feed_article"
specialty: "Oncology"
source_name: "Medical News Today"
source_url: "https://www.medicalnewstoday.com/articles/experimental-pancreatic-cancer-vaccine-shows-promise-in-clinical-trial/"
published_at: "2026-11-07T07:00:00.000Z"
evidence_level: "Verified Feed"
license: "CC-BY-NC-4.0 / Informational Use"
---
# Camupepimut KRAS Vaccine Induces Strong Immune Responses in Phase 2 Pancreatic Cancer Trial
## Provenance & Clinical Metadata
- **Canonical URL:** https://medichelpline.com/clinical-feed/medical-news-today-0-experimental-pancreatic-cancer-vaccine-shows-promise-in-clinical-trial
- **Specialty:** [Oncology](https://medichelpline.com/clinical-feed/oncology.md)
- **Primary Source:** Medical News Today
- **Source URL:** [Original Journal Publication](https://www.medicalnewstoday.com/articles/experimental-pancreatic-cancer-vaccine-shows-promise-in-clinical-trial/)
- **Published At:** 2026-11-07T07:00:00.000Z
- **Evidence Rating:** Verified Feed
## Executive GIST (TL;DR)
- A randomized phase 2 trial (AMPLIFY-7P) tested the experimental vaccine **camupepimut** in 144 patients with resected, **KRAS**-mutated pancreatic ductal adenocarcinoma (stages 1–3) who had completed surgery and chemotherapy. - Participants entered the trial with no radiologic evidence of recurrence; they were randomized 2:1 to vaccine (96 patients) versus observation (48 patients). - The primary endpoint was **disease-free survival**; investigators also measured T-cell immune responses and safety. - The vaccine elicited T-cell responses targeting **KRAS** mutations in nearly 99% of recipients and increased T-cell activity more than ninefold in 82.2% of evaluated participants. - Median disease-free survival was 23.8 months with camupepimut versus 21.2 months in the observation arm; this difference did not reach statistical significance for the trial’s primary endpoint. - At 6 months, 75.7% of vaccinated participants were disease-free versus 61.7% in controls, a numerical early separation that was not statistically significant over full follow-up. - Subgroup analyses suggested better outcomes among patients who had undetectable circulating tumor DNA (ctDNA) at baseline and among participants with stronger T-cell responses. - Safety data: the vaccine was generally well tolerated, with no treatment-related deaths and no discontinuations attributed to adverse events. - The authors reported results in Nature Medicine and plan a phase 3 study to evaluate extended dosing schedules and potential combinations with other therapies. - The source did not report specific dosing schedules, booster timing, combination regimens, statistical values (e.g., p-values), or detailed adverse-event rates beyond the absence of treatment-related deaths or discontinuations.
## Clinical Analysis & Structured Key Points
[Skip to main content](https://www.medicalnewstoday.com/articles/experimental-pancreatic-cancer-vaccine-shows-promise-in-clinical-trial#main) [Medical News Today](https://www.medicalnewstoday.com/) * Health Conditions Health Conditions * [Alzheimer's & Dementia](https://www.medicalnewstoday.com/alzheimers-and-dementia) * [Anxiety](https://www.medicalnewstoday.com/anxiety) * [Asthma & Allergies](https://www.medicalnewstoday.com/asthma-and-allergies) * [Atopic Dermatitis](https://www.medicalnewstoday.com/program/investigating-atopic-dermatitis) * [Breast Cancer](https://www.medicalnewstoday.com/breast-cancer) * [Cancer](https://www.medicalnewstoday.com/cancer) * [Cardiovascular Health](https://www.medicalnewstoday.com/cardiovascular-health) * [COVID-19](https://www.medicalnewstoday.com/coronavirus?correlationId=2b137d5a-dcfb-464e-9ea6-72c5a54b4e92) * [Diabetes](https://www.medicalnewstoday.com/diabetes) * [Endometriosis](https://www.medicalnewstoday.com/endometriosis) * [Environment & Sustainability](https://www.medicalnewstoday.com/environment-and-sustainability) * [Exercise & Fitness](https://www.medicalnewstoday.com/exercise-and-fitness) * [Eye Health](https://www.medicalnewstoday.com/eye-health) * [Headache & Migraine](https://www.medicalnewstoday.com/headache-and-migraine) * [Health Equity](https://www.medicalnewstoday.com/health-equity) * [HIV & AIDS](https://www.medicalnewstoday.com/hiv-and-aids) * [Human Biology](https://www.medicalnewstoday.com/human-biology) * [Leukemia](https://www.medicalnewstoday.com/leukemia) * [LGBTQIA+](https://www.medicalnewstoday.com/LGBTQIA) * [Men's Health](https://www.medicalnewstoday.com/mens-health) * [Mental Health](https://www.medicalnewstoday.com/mental-health) * [Multiple Sclerosis (MS)](https://www.medicalnewstoday.com/multiple-sclerosis) * [Nutrition](https://www.medicalnewstoday.com/nutrition) * [Parkinson's Disease](https://www.medicalnewstoday.com/parkinsons-disease) * [Psoriasis](https://www.medicalnewstoday.com/psoriasis) * [Sexual Health](https://www.medicalnewstoday.com/sexual-health) * [Ulcerative Colitis](https://www.medicalnewstoday.com/program/investigating-ulcerative-colitis) * [Women's Health](https://www.medicalnewstoday.com/womens-health) * Health Products Health Products [All](https://www.medicalnewstoday.com/products-and-reviews) * [Nutrition & Fitness](https://www.medicalnewstoday.com/products-and-reviews/nutrition-and-fitness-products) * [Vitamins & Supplements](https://www.medicalnewstoday.com/products-and-reviews/vitamin-and-supplement-products) * [CBD](https://www.medicalnewstoday.com/products-and-reviews/cbd-products) * [Sleep](https://www.medicalnewstoday.com/products-and-reviews/sleep-products) * [Mental Health](https://www.medicalnewstoday.com/products-and-reviews/mental-health-services-and-products) * [At-Home Testing](https://www.medicalnewstoday.com/products-and-reviews/at-home-testing-products) * [Men’s Health](https://www.medicalnewstoday.com/products-and-reviews/mens-health-products) * [Women’s Health](https://www.medicalnewstoday.com/products-and-reviews/womens-health-products) * Discover News * [Latest News](https://www.medicalnewstoday.com/news) * [Medicare 2026 Costs](https://www.medicalnewstoday.com/articles/medicare-costs-3-key-changes-in-2026) Original Series * [Medical Myths](https://www.medicalnewstoday.com/content-series/medical-myths) * [Honest Nutrition](https://www.medicalnewstoday.com/content-series/honest-nutrition) * [Through My Eyes](https://www.medicalnewstoday.com/content-series/through-my-eyes) * [New Normal Health](https://www.medicalnewstoday.com/content-series/new-normal-health) Podcasts [All](https://www.medicalnewstoday.com/articles/in-conversation-podcast) * [ADHD in women: Breaking the stereotypes](https://www.medicalnewstoday.com/articles/adhd-women-breaking-stereotypes-masking-attention-disorder) * [Is sleep the missing piece in mental health?](https://www.medicalnewstoday.com/articles/is-sleep-the-missing-piece-in-mental-health) * [Artificial sweeteners and brain aging: What we know so far](https://www.medicalnewstoday.com/articles/artificial-sweeteners-and-brain-aging-what-we-know-so-far) * [Does the Mediterranean diet hold the key to longevity?](https://www.medicalnewstoday.com/articles/does-the-mediterranean-diet-hold-the-key-to-longevity) * [AMA: Registered dietitian answers 5 key questions about fiber and weight loss](https://www.medicalnewstoday.com/articles/can-fiber-help-lose-weight-dietitian-answers-5-key-questions) * [Health misinformation and disinformation: How to avoid it](https://www.medicalnewstoday.com/articles/health-misinformation-and-disinformation-how-to-avoid-it) * Tools General Health * [Drugs A-Z](https://www.medicalnewstoday.com/drugs) * [Health Hubs](https://www.medicalnewstoday.com/articles/content-hubs) * [Newsletter](https://www.medicalnewstoday.com/newsletter) * [Medicare Plans by State](https://www.medicalnewstoday.com/about/health-medicare-state-coverage) Health Tools * [Find a Doctor](https://connect.medicalnewstoday.com/) * [BMI Calculators and Charts](https://www.medicalnewstoday.com/articles/323586) * [Blood Pressure Chart: Ranges and Guide](https://www.medicalnewstoday.com/articles/327077) * [Breast Cancer: Self-Examination Guide](https://www.medicalnewstoday.com/articles/316898) * [Sleep Calculator](https://www.medicalnewstoday.com/articles/sleep-calculator) Quizzes * [RA Myths vs Facts](https://www.medicalnewstoday.com/articles/science-fact-or-fiction-separating-ra-myths-from-facts#1) * [Type 2 Diabetes: Managing Blood Sugar](https://www.medicalnewstoday.com/articles/managing-blood-sugar-type-2-diabetes-quiz#1) * [Ankylosing Spondylitis Pain: Fact or Fiction](https://www.medicalnewstoday.com/articles/complementary-therapies-for-as-quiz#1) * Connect About Medical News Today * [Who We Are](https://www.medicalnewstoday.com/about) * [Our Editorial Process](https://www.medicalnewstoday.com/articles/process) * [Content Integrity](https://www.medicalnewstoday.com/about/content-integrity) * [Conscious Language](https://www.medicalnewstoday.com/about/conscious-language) Find Community * [Bezzy Breast Cancer](https://www.bezzybc.com/lp/2/?verzenio&utm_source=mnt&utm_medium=nav-bar-connect) * [Bezzy MS](https://www.bezzyms.com/?utm_source=mnt&utm_medium=nav-bar-connect) * [Bezzy Migraine](https://www.bezzymigraine.com/?utm_source=mnt&utm_medium=nav-bar-connect) * [Bezzy Psoriasis](https://www.bezzypsoriasis.com/?utm_source=mnt&utm_medium=nav-bar-connect) Follow Us [](https://www.facebook.com/MedicalNewsToday/)[](https://x.com/mnt)[](https://www.instagram.com/medicalnewstoday/)[](https://www.linkedin.com/company/mednewstoday/?originalSubdomain=ec)[](https://flipboard.com/@MedNewsToday) Subscribe # Experimental pancreatic cancer vaccine shows promise in clinical trial ![](https://i0.wp.com/post.medicalnewstoday.com/wp-content/uploads/sites/3/2021/10/Erika-Watts-Bio-500x500-1.png?w=105&h=105) Written by Erika Watts on November 7, 2026 — Fact checked by Jill Seladi-Schulman, Ph.D. More cancer resources * **A group of researchers recently conducted a randomized phase 2 trial for a pancreatic cancer vaccine.** * **They found that the vaccine triggered an immune response in nearly 99% of participants.** * **While the vaccine produced a strong immune response, the research team did not find a statistically significant improvement in disease-free survival.** Surgery and chemotherapy can treat [pancreatic cancer](https://www.medicalnewstoday.com/categories/pancreatic-cancer), but cancer cells may remain in the body and [causeTrusted Source](https://www.cancer.gov/types/recurrent-cancer) the disease to return. Researchers are exploring whether cancer vaccines could help the immune system identify and destroy these remaining cells, which could potentially lower the risk of recurrence. A new study examined whether the experimental vaccine camupepimut could help reduce this risk in people who had already undergone surgery and [chemotherapy](https://www.medicalnewstoday.com/articles/323423#treatment). The findings are published in [Nature MedicineTrusted Source](https://www.nature.com/articles/s41591-026-04734-7). ## Experimental vaccine camupepimut According to the [American Cancer SocietyTrusted Source](https://www.cancer.org/cancer/types/pancreatic-cancer/about/key-statistics.html), pancreatic cancer makes up around 3% of cancer cases per year in the United States. Pancreatic cancer is one of the [most difficult cancersTrusted Source](https://www.cancer.gov/types/pancreatic/symptoms) to treat, partly because it often does not have many early warning signs and is not often diagnosed until after it has already spread. [Pancreatic ductal adenocarcinoma](https://www.medicalnewstoday.com/articles/pancreatic-ductal-adenocarcinoma) (PDAC) is the [most common](https://pancan.org/facing-pancreatic-cancer/about-pancreatic-cancer/types-of-pancreatic-cancer/) form of pancreatic cancer. It has a high risk of [recurrence](https://pmc.ncbi.nlm.nih.gov/articles/PMC10463749/), even after surgery and chemotherapy. Mutations in the _KRAS_ gene [occur](https://pmc.ncbi.nlm.nih.gov/articles/PMC11012482/) in around 90% of PDAC cases, which can cause cells to grow uncontrollably and contribute to cancer development. **With this in mind, researchers developed the vaccine camupepimut to target several common _KRAS_ mutations. The vaccine delivers its components to the lymph nodes, where it helps immune cells recognize cancer cells with _KRAS_ mutations.** The researchers described camupepimut as an “off-the-shelf” treatment that could potentially work for people with several _KRAS_ mutations. Unlike [personalized cancer vaccines](https://www.medicalnewstoday.com/articles/novel-mrna-cancer-vaccine-plus-immunotherapy-reduces-melanoma-relapse-phase-3-trial), which are developed based on an individual’s tumor, this approach could make the vaccine more widely available. For the randomized phase 2 AMPLIFY-7P trial, the research team enrolled 144 participants with _KRAS_ -mutated pancreatic cancer (stages 1 to 3). They had surgery and [chemotherapy](https://www.medicalnewstoday.com/articles/158401) treatment before enrolling in the trial. None of the participants showed signs of recurrence on imaging tests when they entered the trial. The researchers divided participants into two groups: * vaccine group (96 participants) * control group (48 participants). The team focused on disease-free survival, or how long they lived without their cancer returning or dying. They also examined immune responses and treatment safety. ## Vaccine boosts immunity, but survival uncertain The researchers found that the vaccine triggered a strong immune response in nearly everyone in the vaccine group. The vaccine activated T cells that target _KRAS_ mutations in nearly 99% of the test group. The vaccine also increased T-cell activity by more than ninefold in 82.2% of those evaluated. Despite these strong immune responses, the vaccine did not meet the study’s primary endpoint for disease-free survival. The median disease-free survival was 23.8 months in the vaccine group compared with 21.2 months in the observation group. **At 6 months, 75.7% of the vaccine group remained disease-free, compared with 61.7% of the control group.** Although this difference suggested a possible early benefit, it did not reach statistical significance. The researchers also did not find a statistically significant improvement in disease-free survival over the full follow-up period. After conducting further analyses, the researchers believe that certain people might benefit more from the vaccine. For example, participants who had no detectable [circulating tumor DNA](https://pmc.ncbi.nlm.nih.gov/articles/PMC10101787/) (ctDNA) at the start of the trial appeared to experience better disease-free survival after vaccination. Detectable ctDNA can indicate that cancer cells remain in the body after treatment. The team also observed an association between stronger [T-cell](https://www.medicalnewstoday.com/articles/cd4-t-cells) responses and longer disease-free survival. The researchers reported that the vaccine was generally well-tolerated, with no treatment-related deaths or adverse events that caused any of the participants to discontinue treatment. The team plans to investigate camupepimut further in a phase 3 trial, potentially using additional booster doses and combining the vaccine with other treatments. ## Vaccine shows promise [Anton Bilchik](https://www.providence.org/doctors/surgical-oncology/ca/santa-monica/anton-bilchik-1609916733), MD, PhD, surgical oncologist, chief of medicine and Director of the Gastrointestinal and Hepatobiliary Program at Providence Saint John’s Cancer Institute, who was not involved in the study, told _Medical News Today_ that the findings are “extremely important” despite the lack of a statistically significant survival benefit. **“It shows that a very resistant cancer such as pancreatic cancer is capable of responding to a vaccine provided the patient develops a strong immune response,” Bilchik explained.** He noted that the study’s small size and limited vaccination period may have influenced the results. “We should therefore interpret these results with optimism recognizing that more studies need to be done to evaluate the benefit in different subsets of patients and in determining the survival benefit when the vaccine is given for a longer period,” Bilchik told us. [Jason Williams](https://williamscancerinstitute.com/dr-jason-williams/), MD, founder and director of interventional oncology and immunotherapy at Williams Cancer Institute, who was also not involved in the study, explained that activating the immune system is only part of the challenge. “Seeing the cancer is the first step,” Williams said. “Clearing it is another.” He suggested that combining the vaccine with other treatments could help overcome pancreatic cancer’s ability to suppress the immune system. > “The immune system needs more than one signal: It has to see the target, and the tumor has to stop shutting it down. A larger randomized trial will have to show patients stay cancer-free longer.” > – Jason Williams, MD * [Pancreatic Cancer](https://www.medicalnewstoday.com/categories/pancreatic-cancer) * [Cancer / Oncology](https://www.medicalnewstoday.com/categories/cancer-oncology) * [Clinical Trials / Drug Trials](https://www.medicalnewstoday.com/categories/clinical_trials) ### How we reviewed this article: History Share this article [](https://www.facebook.com/sharer/sharer.php?u=https%3A%2F%2Fwww.medicalnewstoday.com%2Farticles%2Fexperimental-pancreatic-cancer-vaccine-shows-promise-in-clinical-trial%3Futm_medium%3Dsocial%26utm_source%3Dfacebook%26utm_campaign%3Dsocial-sharebar-referred-desktop "Share on Facebook") [](https://twitter.com/intent/tweet?via=mnt&text=Pancreatic%20cancer%3A%20Experimental%20vaccine%20boosts%20survival%20in%20trial&url=https%3A%2F%2Fwww.medicalnewstoday.com%2Farticles%2Fexperimental-pancreatic-cancer-vaccine-shows-promise-in-clinical-trial%3Futm_medium%3Dsocial%26utm_source%3Dx%26utm_campaign%3Dsocial-sharebar-referred-desktop "Share on X") ![](https://i0.wp.com/post.medicalnewstoday.com/wp-content/uploads/sites/3/2021/10/Erika-Watts-Bio-500x500-1.png?w=105&h=105) Written by Erika Watts on November 7, 2026 — Fact checked by Jill Seladi-Schulman, Ph.D. ## Was this article helpful? YesNo [](https://www.facebook.com/MedicalNewsToday/)[](https://x.com/mnt)[](https://www.pinterest.com/medicalnewstoday/?eq=medical%20news%20today&etslf=4441)[](https://www.instagram.com/medicalnewstoday/)[](https://www.youtube.com/channel/UC7snF15Idi7px6XujWe_h9A)[](https://flipboard.com/@MedNewsToday) ## Get our newsletter Keep up with the ever-changing world of medical science with new and emerging developments in health. Enter your email SUBSCRIBE Your [privacy](https://www.medicalnewstoday.com/about/privacy-notice) is important to us © 2026 Healthline Media UK Ltd, London, UK. All rights reserved. MNT is the registered trade mark of Healthline Media. Healthline Media is an RVO Health Company. Any medical information published on this website is not intended as a substitute for informed medical advice and you should not take any action before consulting with a healthcare professional. [See additional information](https://www.medicalnewstoday.com/about/additional-information). * [About Us](https://www.medicalnewstoday.com/about) * [Contact Us](https://www.medicalnewstoday.com/about/contact-us) * [Terms of Use](https://www.medicalnewstoday.com/about/terms-of-use) * [Privacy Notice](https://www.medicalnewstoday.com/about/privacy-notice) * Privacy Settings * [Advertising Policy](https://www.medicalnewstoday.com/ad-policy) * [Licensing Requests](https://permissions.rvohealth.threesai.com/) * [Health Topics](https://www.medicalnewstoday.com/directory/a-b) * [Health Hubs](https://www.medicalnewstoday.com/articles/content-hubs) * [Medical Affairs](https://www.medicalnewstoday.com/about/reviewers) * [Content Integrity](https://www.medicalnewstoday.com/about/content-integrity) * [Newsletters](https://www.medicalnewstoday.com/newsletter) * [Your Privacy Choices](https://privacyportal.onetrust.com/webform/b45407c6-ee79-4a08-912e-02ce898f9a14/6a88ff3d-e0ff-44b3-bb05-e8a2a65072fe?anonymousId=bcca095b-968c-45b9-967f-5add60cc45ca&orgId=c69bb2d7-c8f5-4d6f-a080-8c2266e12003)![CCPA Privacy Options Logo](https://i0.wp.com/assets.healthline.com/content/ccpaprivacyoptions29x14.png) [](https://www.fullspanhealth.com/) [About](https://www.healthlinemedia.com/?utm_source=medicalnewstoday.com&utm_medium=site&utm_campaign=footer&utm_content=about)[Careers](https://rvohealth.com/careers)[Advertise with us](https://www.healthlinemedia.com/advertise?utm_source=medicalnewstoday.com&utm_medium=site&utm_campaign=footer&utm_content=advertise) OUR BRANDS [Healthline](https://www.healthline.com/)[Medical News Today](https://www.medicalnewstoday.com/)[Greatist](https://greatist.com/)[Psych Central](https://psychcentral.com/)[Bezzy](https://bezzy.com/) [![This website is certified by AACI. Click to verify.](https://media.post.rvohealth.io/wp-content/uploads/2026/03/image-1.png)](https://aacihealthcare.com/certificates/c143-2-2021-trust-usa/) ![](https://www.medicalnewstoday.com/navi/reinforce?&domain=medicalnewstoday.com) ## History 1. Current version Written by Erika Watts
## Related Clinical Research

- [High-fat Diets Reprogram Intestinal Stem Cells and May Raise Colon Cancer Risk](https://medichelpline.com/clinical-feed/medical-news-today-0-high-fat-diets-leave-memory-in-gut-stem-cells-that-may-fuel-colon-cancer.md)
- [Supplement reported to ease brain fog and fatigue after breast cancer treatment](https://medichelpline.com/clinical-feed/medical-news-today-0-supplement-shows-promise-for-brain-fog-and-fatigue-after-breast-cancer-treatment.md)
- [Climate change worsens health for people with chronic illness](https://medichelpline.com/clinical-feed/stat-news-1-opinion-climate-change-is-making-people-with-chronic-illness-even-sicker.md)
- [Sellas Phase 3 REGAL trial for galinpepimut-S faces delays and likely negative outcome in AML](https://medichelpline.com/clinical-feed/stat-news-1-stat-a-sellas-immunotherapy-study-long-delayed-will-end-in-failure.md)
- [COVID-19 and later risk of neurodegenerative and neurological disorders in vaccinated and unvaccin](https://medichelpline.com/clinical-feed/medrxiv-19-association-of-covid-19-with-neurodegenerative-and-neurological-disorders-in.md)

## Navigation
- [← Back to Oncology Feed](https://medichelpline.com/clinical-feed/oncology.md)
- [← All Clinical Specialties](https://medichelpline.com/clinical-feed.md)
## Medical & Regulatory Disclaimer

> [!CAUTION]
> MedicHelpline content is structured for research, educational, and professional discovery purposes. It does not constitute individual medical advice, clinical diagnosis, or treatment recommendations.
> Always verify dosing, contraindications, and regulatory alerts against official product labeling and primary regulatory sources before clinical decision-making.